Literature DB >> 16809922

Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma.

Carolina Cristina1, Isabel García-Tornadú, Graciela Díaz-Torga, Marcelo Rubinstein, Malcolm J Low, Damasia Becú-Villalobos.   

Abstract

Dopamine receptor type 2 (D2R) knockout mice (KO) have chronic hyperprolactinemia, pituitary hyperplasia, and a moderate decrease in MSH content. They are also growth retarded evidencing an alteration in the GH-IGF-I axis. In D2R KO, lactotropes do not show dense secretory granules but degranulated cells and fewer somatotropes, gonadotropes and thyrotropes. Prolactin levels are always higher in female than in male knockouts, and in accordance, pituitary hyperplasia is observed at 8 months only in females. After 16 months of age, highly vascularized adenomas develop, especially in females. Prominent vascular channels in the hyperplastic and adenomatous pituitaries, as well as extravasated red blood cells not contained in capillaries is also a common finding. Prolactin is not the factor that enhances the hyperplastic phenotype in females while estrogen is a permissive factor. VEGF-A expression is increased in pituitaries from D2R KO. VEGF-A is expressed in follicle stellate cells. Because D2R receptors are found in lactotropes and not in follicle stellate cells, it may be inferred that a paracrine-derived factor from lactotropes is acting on follicle stellate cells to increase VEGF-A expression. VEGF-A does not induce pituitary cell proliferation, even though it enhances prolactin secretion. But it may act on adjacent endothelial cells and participate in the angiogenic process that increases the availability of different growth factors and mitogens. The D2R knockout mouse represents a unique animal model to study dopamine-resistant prolactinomas, and VEGF-A may be an alternative therapeutic target in this pathology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809922     DOI: 10.1159/000094308

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  14 in total

1.  A combined opiate agonist and antagonist treatment reduces prolactin secreting pituitary tumor growth.

Authors:  George Maglakelidze; Olivia Wynne; Dipak K Sarkar
Journal:  J Cell Commun Signal       Date:  2017-01-31       Impact factor: 5.782

2.  VEGF and CD31 association in pituitary adenomas.

Authors:  Carolina Cristina; María Inés Perez-Millan; Guillermina Luque; Raúl Ariel Dulce; Gustavo Sevlever; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

3.  Comparison of the temporal programs regulating tyrosine hydroxylase and enkephalin expressions in TIDA neurons of lactating rats following pup removal and then pup return.

Authors:  Flora Klara Szabó; Wei-Wei Le; Natalie S Snyder; Gloria E Hoffman
Journal:  J Mol Neurosci       Date:  2010-12-02       Impact factor: 3.444

Review 4.  The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Graciela Díaz-Torga
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

Review 5.  Dopamine signaling and myopia development: What are the key challenges.

Authors:  Xiangtian Zhou; Machelle T Pardue; P Michael Iuvone; Jia Qu
Journal:  Prog Retin Eye Res       Date:  2017-06-07       Impact factor: 21.198

6.  Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary.

Authors:  M Victoria Recouvreux; M Clara Guida; Daniel B Rifkin; Damasia Becu-Villalobos; Graciela Díaz-Torga
Journal:  Endocrinology       Date:  2011-04-26       Impact factor: 4.736

7.  Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.

Authors:  María Susana Mallea-Gil; Carolina Cristina; María Inés Perez-Millan; Ana M Rodriguez Villafañe; Carolina Ballarino; Graciela Stalldecker; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

8.  Pituitary adenoma with peliosis: a report of two cases.

Authors:  Safraz Mohammed; Luis V Syro; Bernd W Scheithauer; Alberto Abad; Humberto Uribe; Fabio Rotondo; Eva Horvath; Michael Cusimano; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.

Authors:  Carolina Cristina; Graciela S Díaz-Torga; Rodolfo G Goya; Sham S Kakar; María I Perez-Millán; Vanessa Q Passos; Daniel Giannella-Neto; Marcello D Bronstein; Damasia Becu-Villalobos
Journal:  Mol Cancer       Date:  2007-01-12       Impact factor: 27.401

Review 10.  The role of genetic and epigenetic changes in pituitary tumorigenesis.

Authors:  Hidenori Fukuoka; Yutaka Takahashi
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-11-29       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.